Full Press Release Details
Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S..
KYTX
Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.
Key Takeaway: Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.